Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report released on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $23.00 price objective on the stock.

A number of other equities analysts have also commented on AVTX. BTIG Research began coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $18.00 target price on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Stifel Nicolaus initiated coverage on shares of Avalo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $36.00 target price on the stock. Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective for the company. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Avalo Therapeutics Stock Up 11.9 %

NASDAQ AVTX opened at $8.54 on Tuesday. The firm’s 50-day simple moving average is $7.51 and its two-hundred day simple moving average is $9.14. Avalo Therapeutics has a 52 week low of $4.60 and a 52 week high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its position in Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Avalo Therapeutics in the 4th quarter worth $114,000. Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at approximately $145,000. Northern Trust Corp bought a new position in Avalo Therapeutics during the fourth quarter valued at $168,000. Finally, Bank of Montreal Can bought a new stake in Avalo Therapeutics in the fourth quarter worth about $446,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.